Hospital
Northcrest Medical Center
Northcrest Medical Center was paid $6.96M by Medicaid between Jan 2018 and Aug 2021, across 84 billing codes. Its largest line is 99285, emergency room visit (most serious) — 40% of everything it billed.
33Billing provider infoNORTHCREST MEDICAL CENTER
SPRINGFIELD, TN 37172
SPRINGFIELD, TN 37172
33aNPI1669567897assigned 10/04/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.96M
24GClaims153,635
24DCodes billed84
24AFirst – last monthJan 2018 – Aug 2021
Compared with peers
Next to other General Acute Care Hospital providers in Tennessee
Rank by total paid#36 of 71
Median peer was paid$6.96M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 48,086 | $2.26M | |
| 2019 | 48,953 | $2.08M | |
| 2020 | 31,967 | $1.45M | |
| 2021 | 24,629 | $1.16M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 40% | 11,335 | 10,193 | $2.78M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 23% | 9,092 | 8,393 | $1.61M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 9,930 | 9,367 | $1.59M |
| G0378 | Hospital observation service, per hour | 2.8% | 1,386 | 1,224 | $192K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 954 | 918 | $142K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,856 | 6,163 | $67K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,979 | 1,863 | $55K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13,175 | 11,391 | $46K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,189 | 453 | $44K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 679 | 621 | $38K |
| 84484 | <1% | 4,034 | 3,053 | $35K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,427 | 1,271 | $33K |
72 more codes
| 80053 | Comprehensive metabolic panel | <1% | 12,116 | $31K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,995 | $30K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 594 | $24K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 656 | $21K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,357 | $17K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,265 | $15K |
| 36415 | Collection of venous blood by venipuncture | <1% | 14,686 | $15K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,926 | $13K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,861 | $12K |
| 83690 | <1% | 3,229 | $11K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,638 | $11K |
| 85730 | <1% | 3,503 | $9K | |
| 83605 | <1% | 2,178 | $8K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,636 | $8K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,665 | $7K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 607 | $7K |
| 83874 | <1% | 1,226 | $7K | |
| 85610 | <1% | 3,822 | $6K | |
| 59025 | Fetal non-stress test | <1% | 408 | $6K |
| 87430 | <1% | 1,236 | $6K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 31 | $6K |
| 81025 | <1% | 2,435 | $6K | |
| 81003 | <1% | 7,812 | $5K | |
| 87634 | <1% | 140 | $4K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 13 | $4K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 170 | $4K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,894 | $3K |
| 87081 | <1% | 1,118 | $3K | |
| 87040 | <1% | 778 | $3K | |
| 87400 | <1% | 911 | $3K | |
| 97597 | <1% | 52 | $2K | |
| 96376 | <1% | 688 | $2K | |
| 85027 | <1% | 980 | $2K | |
| 85379 | <1% | 302 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 110 | $1K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 30 | $1K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 26 | $1K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 12 | $910.82 |
| 80299 | <1% | 111 | $884.10 | |
| 82962 | <1% | 432 | $838.63 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 42 | $805.60 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 165 | $739.81 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 39 | $468.87 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 292 | $445.60 |
| 84702 | <1% | 41 | $430.25 | |
| 87301 | <1% | 42 | $413.90 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 30 | $326.62 |
| 82803 | <1% | 56 | $286.20 | |
| 73630 | <1% | 34 | $269.33 | |
| 94727 | <1% | 13 | $265.95 | |
| 81001 | <1% | 473 | $250.50 | |
| 87420 | <1% | 39 | $243.28 | |
| 83735 | <1% | 61 | $216.81 | |
| 82150 | <1% | 62 | $210.65 | |
| 94729 | <1% | 13 | $199.84 | |
| 87186 | <1% | 32 | $178.99 | |
| 80061 | Lipid panel | <1% | 15 | $172.68 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 511 | $170.73 |
| 83880 | <1% | 41 | $166.59 | |
| 84703 | <1% | 31 | $132.30 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 26 | $66.05 |
| 87088 | <1% | 14 | $47.28 | |
| 82550 | <1% | 15 | $38.30 | |
| 87070 | <1% | 17 | $18.50 | |
| 87385 | <1% | 13 | $12.88 | |
| 87205 | <1% | 17 | $9.18 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 122 | $0.00 |
| A9270 | Non-covered item or service | 0% | 41 | $0.00 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 35 | $0.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 96 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 506 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDAVIS, RANDALL (CEO)
| Provider | Location | Paid |
|---|---|---|
| Randall L Davis DMD PC | Lawrence, MA | $5.64M |
| Davis Dental PC | Cheyenne, WY | $6K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.